Eli Lilly (LLY)

Gary Black calls Eli Lilly's valuation 'compelling' as Q1 earnings soar, driven by the consumer 'love affair' with GLP-1 weight loss drugs.

Eli Lilly stock rallies as GLP-1 sales drive a 56% year-on-year increase in Q1 revenue. Jim Cramer recommends buying LLY shares as the weight-loss addressable market is truly huge.

Eli Lilly (LLY) Q1 2026 Earnings Transcript

GLP-1 drugs turned Lilly into a powerhouse. Now it's time to write the next chapter -- in cancer.

Eli Lilly beats Q1 estimates, lifts 2026 outlook as Mounjaro and Zepbound demand offsets pricing pressure and drives strong revenue growth.

Eli Lilly stock popped early Thursday after the drugmaker crushed first-quarter sales forecasts and hiked its 2026 guidance.

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 55.5% year on year to ...

The biotech's candidate may treat a great number of illnesses that have one thing in common.

Eli Lilly & Co. (LLY) will release Q1 earnings on April 30. Analysts expect $6.79/share, up from $3.34/share last year. LLY down 2.6% on Wed.

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results this Thursday before market hours. Here’s what to expect. Eli Lilly beat analyst...

And he may be right.

What Happened? Shares of personal wellness company WeightWatchers (NASDAQ:WW) fell 5.3% in the afternoon session after the company announced its intention to...

The drugmaker is getting on the AI train in ways that could move the needle down the road.

Eli Lilly has more to offer than some investors realize.

Hims & Hers stock rallied on Friday on a major regulatory update and bullish analyst note. Here’s how high HIMS shares could realistically fly through the end of 2026.

Eli Lilly shares sink as data shows Foundayo trailing Novo’s oral Wegovy. But there’s reason to consider buying LLY shares on the dip today.

This pharma stock is cheap for a reason.